Frontiers in Medicine (Jun 2023)

Sustained agreement rates in the longitudinal assessment of lupus patients to a Broad Consent for personal data and specimen usage in the RHINEVIT biobank

  • Jutta G. Richter,
  • Jutta G. Richter,
  • Tim Filla,
  • Tim Filla,
  • Hasan Acar,
  • Hasan Acar,
  • Ellen Bleck,
  • Ellen Bleck,
  • Anna Kernder,
  • Anna Kernder,
  • Christina Düsing,
  • Christina Düsing,
  • Stefan Vordenbäumen,
  • Stefan Vordenbäumen,
  • Markus Schröder,
  • Ralf Hansen,
  • Jörg H. W. Distler,
  • Jörg H. W. Distler,
  • Matthias Schneider,
  • Matthias Schneider

DOI
https://doi.org/10.3389/fmed.2023.1208006
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundBiobanks are essential structures for scientific research. The RHINEVIT biobank is used to recruit biomaterials from rheumatology patients in outpatient care and to conduct clinical research studies (e.g., cohort studies) and basic research. RHINEVIT established Broad Consents (BC) to allow extensive and relevant usage of data and biospecimens without the need for specific project restrictions. For quality assurance, we compared the consent rate of individual items of the BC versions in patients with systemic lupus erythematosus (SLE) in the longitudinal study.MethodsBCs were used for biomaterial donation. Informed consent data from RHINEVIT were analyzed. Due to the content restructuring of the BC items due to changes from the templates of the working group of the Medical Ethics Commissions in the Federal Republic of Germany and GDPR requirements, content mapping of the items was performed for the analysis.ResultsFrom September 2015 to March 2022, 291 SLE outpatients donated biomaterials. In 119 patients, the BC was renewed at least once in a subsequent biomaterial donation. Three biomaterial donations were obtained from 21 patients and four from six patients using the respective BC. However, one consent was later revoked. Consent to the BC topics showed consistently high rates of agreement (range 97.5%−100%), with only some patients disagreeing with individual topics. This remained stable over time (median 526 days [Q1 400, Q3 844]). None of the patients disagreed with a certain topic in two consecutive visits.ConclusionModifications to the BC did not result in any relevant changes in the approval rates for SLE patients. RHINEVIT's BC is successfully used for the quality-assured handling of excellently annotated biomaterial. The long-term use of these highly valuable biospecimens for unrestricted research, also in an international context, remains assured.

Keywords